- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.06. | Iconovo AB: Iconovo and Lonza sign Strategic Collaboration Agreement | 283 | GlobeNewswire (Europe) | Iconovo AB (publ.) announces today that it has signed a strategic collaboration agreement with Lonza on the basis of the Letter of Intent (LOI) announced in February of this year. The agreement aims... ► Artikel lesen | |
| 24.04. | Iconovo AB: Quarterly Report Q1 2026 | 679 | GlobeNewswire (Europe) | SIGNIFICANT EVENTS DURING 1 JANUARY - 31 MARCH 2026In January 2026, it was announced that the European Patent Office (EPO) had declared its intention to grant Iconovo's patent application for ICOpre®.... ► Artikel lesen | |
| 14.04. | Iconovo AB: Anders Månsson is appointed CEO | 186 | GlobeNewswire (Europe) | Iconovo AB (publ) has today appointed Anders Månsson as permanent CEO of Iconovo AB after approximately 6 months of service as interim CEO.
Anders Månsson has worked in the company as interim CEO since... ► Artikel lesen | |
| 02.03. | Iconovo AB: Iconovo announces final outcome in the rights issue | 376 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND... ► Artikel lesen | |
| 27.02. | Iconovo AB: Iconovo publishes preliminary outcome of rights issue and announces recalculation of warrants series TO 1 | 231 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND... ► Artikel lesen | |
| 24.02. | Iconovo AB: Iconovo and Lonza signs LOI regarding strategic collaboration | 380 | GlobeNewswire (Europe) | Iconovo AB (publ.) today announces that it has signed a Letter of Intent (LOI) with Lonza with the aim of forging a lasting strategic collaboration in the area "spray dried formulation" capabilities... ► Artikel lesen | |
| 13.02. | Iconovo AB: The subscription period in Iconovo's rights issue begins today | 315 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND... ► Artikel lesen | |
| ICONOVO Aktie jetzt für 0€ handeln | |||||
| 12.02. | Iconovo AB: Iconovo publishes information document regarding rights issue of shares | 187 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND... ► Artikel lesen | |
| 12.02. | Iconovo AB: Year-end report 1 January - 31 December 2025 | 623 | GlobeNewswire (Europe) | SIGNIFICANT EVENTS DURING 1 OCTOBER - 31 DECEMBER 2025In mid-October, the company announced that it is withdrawing the financial targets communicated on 1 June 2022. The targets are currently under... ► Artikel lesen | |
| 15.01. | Iconovo AB: Iconovo has initiated a new feasibility study for ICOone Nasal in collaboration with multinational company | 330 | GlobeNewswire (Europe) | Iconovo AB (publ.), a leader in the development of inhalable drugs based on proprietary inhalers and dry powder formulations, today announces that it has agreed to conduct a feasibility study on behalf... ► Artikel lesen | |
| 25.11.25 | Iconovo AB: Iconovo carries out a directed issue of shares of approx. SEK 25 million and a rights issue of shares of approx. SEK 24.6 million, which is covered to 100% by subscription undertakings and guarantee commitments | 188 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND... ► Artikel lesen | |
| 31.10.25 | Iconovo AB: Iconovo appoints new CEO | 275 | GlobeNewswire (Europe) | Iconovo AB (publ), a leader in the development of inhalable drugs based on proprietary inhalers and dry powder formulations, has today appointed Anders Månsson as interim CEO of Iconovo AB. The Board... ► Artikel lesen | |
| 24.10.25 | Iconovo AB: Quarterly Report Q3 2025 | 266 | GlobeNewswire (Europe) | SIGNIFICANT EVENTS DURING 1 JULY - 30 SEPTEMBER 2025During the third quarter, Iconovo carried out a reorganization to focus on the three largest near-term opportunities: ICOpre, ICOres, and the development... ► Artikel lesen | |
| 14.10.25 | Iconovo AB: Iconovo reworks its strategic goals | 298 | GlobeNewswire (Europe) | Iconovo AB (publ), a leading company in the development of inhalable medicines based on proprietary inhalers and dry powder formulations, today announces that it is leaving the financial targets communicated... ► Artikel lesen | |
| 14.07.25 | Iconovo AB: Quarterly Report Q2 2025 | 663 | GlobeNewswire (Europe) | SIGNIFICANT EVENTS DURING 1 APRIL - 30 JUNE 2025In April, Iconovo announced an organizational change expected to reduce annual costs by approximately 14-16 MSEK starting in the third quarter of 2025.... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 50,12 | -1,14 % | Milliarden-Showdowns vs. Psychedelika-Boom: Warum Pharma-Riesen wie Bayer und Regeneron plötzlich auf die Nische blicken | ||
| MERCK KGAA | 139,70 | +0,07 % | Stimmung im Biotech-Sektor dreht sich - Milliardendeals, neue Plattformen und mehr Kapital | ||
| NOVO NORDISK | 43,320 | -0,13 % | Novo Nordisk: Zahlt sich dieser Deal aus? | Im Jahr 2020 hat sich Novo Nordisk die Dienste der Biotech-Gesellschaft Corvidia Therapeutics gesichert. Kostenpunkt: 725 Millionen Dollar plus potenzielle Meilensteinzahlungen, die den Transaktionswert... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,120 | 0,00 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Reaffirms guidance to resubmit Anaphylm (dibutepinephrine) sublingual film NDA in Q3 2026Affirms existing clinical data is sufficient for submitting regulatory applications in Canada, European Union... ► Artikel lesen | |
| SCHOTT PHARMA | 20,200 | +1,00 % | DEUTSCHE BANK RESEARCH stuft Schott Pharma auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Schott Pharma von 16 auf 22 Euro angehoben und die Aktien von "Hold" auf "Buy" hochgestuft. Der Spezialist für Verpackung und... ► Artikel lesen | |
| DERMAPHARM | 45,500 | -0,11 % | Dividendenbekanntmachungen (29.06.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AGC INC JP3112000009 105 JPY 0,5701 EUR ALTER EGO MEDIA SA GRS541003000 - 0,03 EUR AOZORA BANK LTD JP3711200000 23 JPY 0,1248... ► Artikel lesen | |
| PMGC | 1,110 | -0,89 % | PMGC Holdings Inc.: NorthStrive Biosciences to Advance EL-22 Manufacturing Characterization with Quantitative FACS Analysis of Latent Myostatin Antigen Expression | Independent flow cytometry (FACS) study will quantify latent myostatin antigen expression on NorthStrive-manufactured Lactobacillus casei and establish comparability against EL-22 material previously... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 14,330 | +0,03 % | Generate:Biomedicines: Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update | SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance
Clinical trial sites activated for GB-4362 (MMAE neutralizer); first... ► Artikel lesen | |
| ASTRAZENECA | 150,90 | +0,37 % | BERNSTEIN RESEARCH stuft ASTRAZENECA auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat das Kursziel für Astrazeneca von 18600 auf 18900 Pence angehoben und die Einstufung auf "Outperform" belassen. Vielversprechende... ► Artikel lesen | |
| PFIZER | 21,185 | -0,05 % | JPMORGAN stuft PFIZER INC auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat das Kursziel für Pfizer von 30 auf 28 US-Dollar gesenkt und die Einstufung auf "Neutral" belassen. Seine Schätzungen für die Quartalszahlen am... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 13,540 | -0,15 % | Kazia Therapeutics Limited: Kazia Therapeutics Appoints James Levine as Chief Financial Officer | SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 77,84 | 0,00 % | Motorola Solutions Foundation and Calculated Genius Honor Chicagoland Future Engineers With 2026 Bright Minds, Bold Futures Scholarship | NORTHAMPTON, MA / ACCESS Newswire / June 30, 2026 / Ten extraordinary Chicagoland high school seniors recently gathered at Motorola Solutions' global headquarters in Chicago, joined by family members... ► Artikel lesen | |
| KARDIGAN | 24,550 | -0,34 % | Kardigan, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Kardigan, Inc. (Nasdaq: KARD) ("Kardigan"), a clinical-stage precision therapeutics company developing medicines that target the root... ► Artikel lesen | |
| ELI LILLY | 1.044,80 | +0,36 % | Megatrend Folger: Eli Lilly sprengt die Billionen-Marke | Eli Lilly marschiert weiter an der Spitze des globalen Gesundheitssektors. Die Aktie des US-Pharmagiganten kletterte am Dienstag auf ein neues Allzeithoch und lässt damit die Marke von einer Billion... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 36,720 | +0,30 % | Eton Pharmaceuticals Aktie erreicht Rekordhoch von 38,6 USD |
ICONOVO AB gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ICONOVO AB finden Sie auf Wallstreet Online.